Ms. Rosario’s extensive experience in clinical development and human ethics in clinical trials qualifies her to be the first to join Sanguine’s Clinical Advisory Board and Ethics Committee. Prior to joining Biothera Inc., Ms. Rosario held several senior positions with MannKind Corp., serving...

MannKind Corp., the Valencia-based biomedical firm bankrolled by billionaire Alfred Mann, widened its third-quarter loss to $42.8 million (22 cents per share) from $38.4 million (31 cents attributed to fewer shares) a year earlier. The company, which has not yet brought a product to market, increased...

Valencia-based MannKind Corp. announced Friday it has completed recruiting patients for two Phase 3 clinical studies of Afrezza (insulin human [rDNA origin]), an investigational, ultra rapid-acting mealtime insulin therapy, administered using MannKind’s to-be-marketed next-generation inhaler. The...

Valencia-based drug developer MannKind Corp. continued to bleed money during the second quarter of 2012 as it awaits FDA approval for its candidate diabetes cure, called Afreeza. Still reeling from last year’s setbacks when the government ordered it to conduct more clinical trials of its revolutionary...

[MannKind Corp.] – Results published in Blood, the official journal of the American Society of Hematology, confirm that inhibition of the IRE1α-XBP1 pathway impacts the survival of myeloma cells, suggesting a promising therapeutic option in multiple myeloma. The pre-clinical study, conducted by...

[MannKind] – Valencia-based pharmaceutical developer MannKind Corp. said Monday it has signed an agreement worth $130 million with Salt Lake City-based Tolero Pharmaceuticals to develop and commercialize certain compounds MannKind is developing currently being developed to treat hematological malignancies...

Valencia pharmaceutical developer MannKind Corp. cut its expenses and trimmed its losses slightly in 2011, and recently extended the repayment schedule of the loan from its principal shareholder, billionaire investor Alfred Mann. Founded by Mann in 1991, the company doesn’t yet have an approved...

[MannKind Corp.] – Valencia-based MannKind Corp. announced Tuesday that it reached a final resolution of the arbitration proceedings initiated by John Arditi, MannKind’s former Senior Director-GCP, Regulatory Affairs. During his employment with MannKind, Mr. Arditi played a key role in preparing...

[Alfred Mann Fdn., Santa Clarita, Calif] – Today the Federal Communications Commission ruled in favor of allocating secure secondary spectrum for transformative medical technology. The spectrum will provide the radio frequency required to power a number of implantable medical devices that will...

Valencia pharmaceutical company MannKind Corp. shaved its third-quarter loss to $38.5 million (31 cents per share) from $45.3 million (40 cents a year ago) on a 26 percent decrease in expenses for research and development. The company made the announcement at the close of trading Thursday. The loss beat...